Giannetti Matthew P, Cardet Juan C
Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, 75 Francis St. Smith Building, 628, Boston, MA, 02115, USA.
Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, 75 Francis St., Boston, MA, 02115, USA.
Curr Allergy Asthma Rep. 2016 Nov;16(11):80. doi: 10.1007/s11882-016-0662-1.
Asthma is the most common chronic respiratory disease in the USA. A subset of patients with asthma have refractory symptoms, persistent eosinophilic inflammation, and recurrent exacerbations despite maximal medical therapy. The monoclonal antibodies targeting the IL-5 pathway are a new class of medications designed to target severe eosinophilic asthma. There are two medications clinically available: mepolizumab and reslizumab, both of which target IL-5. A third medication, benralizumab, is currently under development and targets the IL-5 receptor. Clinical data suggest these medications can reduce asthma exacerbations and improve lung function in patients with peripheral eosinophilia and poorly controlled asthma despite maximal medical therapy. The anti-IL-5 medications are among the first targeted molecular therapies for asthma and will usher in an exciting new era in the treatment of severe asthma.
哮喘是美国最常见的慢性呼吸道疾病。一部分哮喘患者尽管接受了最大程度的药物治疗，但仍有难治性症状、持续性嗜酸性粒细胞炎症和反复加重的情况。靶向白细胞介素-5（IL-5）通路的单克隆抗体是一类旨在治疗重度嗜酸性粒细胞性哮喘的新型药物。目前有两种临床可用药物：美泊利单抗和瑞利珠单抗，二者均靶向IL-5。第三种药物贝那利珠单抗目前正在研发中，靶向IL-5受体。临床数据表明，这些药物可减少外周血嗜酸性粒细胞增多且哮喘控制不佳、尽管接受了最大程度药物治疗的患者的哮喘加重次数，并改善其肺功能。抗IL-5药物是首批用于哮喘治疗的靶向分子疗法，将开创重度哮喘治疗的一个令人兴奋的新时代。
